@article{27e4dff6121e4820981697fd4b4c0c8e,
title = "Reply to {"}Inferring clinical relevance of der p 23 from the restricted effect on treatment outcomes after tablet allergy immunotherapy{"}",
keywords = "Humans, Hypersensitivity, Immunoglobulin E, Sublingual Immunotherapy, Tablets, Treatment Outcome",
author = "Thomas Stranzl and Henrik Ipsen and Christensen, \{Lars Harder\} and Thomas Eiwegger and Niels Johansen and Kaare Lund and Andersen, \{Peter Sejr\}",
note = "Funding Information: HI, LHC, NJ, KL and PSJ are ALK A/S shareholders. TS, LHC, NJ and PSJ are employees of ALK A/S. HI and KL are consultants for ALK A/S. Dr Eiwegger reports other from DBV, grants from Innovation fund Denmark, Regeneron, outside the submitted work; investigator initiated oral immunotherapy trials supported by the Allergy and Anaphylaxis Program Sickkids; associate editor for Allergy. Thomas Eiwegger receives a grant outside the submitted work from ALK A/S. Local advisory board ALK A/S. In kind contributions from MacroArray Diagnostics outside of the submitted work. ",
year = "2021",
month = apr,
doi = "10.1111/all.14636",
language = "English",
volume = "76",
pages = "1300--1301",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",
}